Description
BML 111 is a FPR2 (lipoxin A4 receptor) agonist. It inhibits tumor-related angiogenesis and reduces tumor growth in hepatoma H22 cell bearing mice. BML 111 also protects against hemorrhagic shock-induced acute lung injury in rats and attenuates renal ischemia/reperfusion injury